T-DXd
Breast Cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
Iwata H, Xu B, Kim S-B, et al.
Cancer Sci. 2024;115(9):3079-3088. doi: 10.1111/cas.16234. Epub 2024 Jul 9.
HER3-DXd
Lung Cancer
Real-world treatment patterns and clinical outcomes among patients with metastatic or unresectable EGFR-mutated non-small cell lung cancer previously treated with osimertinib and platinum-based chemotherapy
Patel J, Meng J, Le H, et al.
Adv Ther. 2024;41(8):3299-3315. doi: 10.1007/s12325-024-02936-4. Epub 2024.
Valemetostat
Lung Cancer
A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small-cell lung cancer
Choudhury NJ, Lai WV, Makhnin A, et al.
Clin Cancer Res. 2024;30(17):3697-3703. doi: 10.1158/1078-0432.CCR-23-3383.
T-DXd
Breast Cancer
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: Subgroup analysis of the DESTINY-Breast04 study
Yamashita T, Sohn JH, Tokunaga E, et al.
Breast Cancer. 2024;31(5):858-868. doi: 10.1007/s12282-024-01600-7.
T-DXd
Breast Cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: Long-term survival analysis of the DESTINY-Breast03 trial
Cortés J, Hurvitz SA, Im S-A, et al.
Nat Med. 2024;30(8):2208-2215. doi: 10.1038/s41591-024-03021-7.
T-DXd
Gastric Cancer
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: Exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial
Shitara K, Bang Y-J, Iwasa S, et al.
Nat Med. 2024;30(7):1933-1942. doi: 10.1038/s41591-024-02992-x.
Dato-DXd
Breast Cancer
Datopotamab deruxtecan in advanced or metastatic HR+/HER2- and triple-negative breast cancer: Results from the phase I TROPION-PanTumor01 study
Bardia A, Krop IE, Kogawa T, et al.
J Clin Oncol. 2024;42(19):2281-2294. doi: 10.1200/JCO.23.01909. Epub 2024 Apr 2
T-DXd
Breast Cancer
Other/Multi
Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: Analysis of the phase Ib DS8201-A-U105 study
Hamilton E, Galsky MD, Ochsenreither S, et al.
Clin Cancer Res. 2024;30(24):5548-5558. doi: 10.1158/1078-0432.CCR-24-1513
Quizartinib
Other/Multi
A study to learn how well quizartinib with chemotherapy works and how safe it is in people with acute myeloid leukemia that is FLT3-ITD-positive: A plain language summary of the QuANTUM-First study
Erba HP
Future Oncol. 2024:1-15. doi: 10.1080/14796694.2024.2422261.
HER3-DXd
Tumor-agnostic
Prevalence of HER3 expression in pancreatic cancer patients treated with systemic chemotherapy
Satake T, Morizane C, Okada M, et al.
Cancer Med. 2024;13(23):e70474. doi: 10.1002/cam4.70474.